Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Sleep Medicine|May 22, 2007
A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndromeRussell Rosenberg, James M Roach, Martin Scharf, et al.Journal of Drugs in Dermatology : JDD|March 17, 2017
Dermatologists: Collaborating With Payers to Optimize Coverage PoliciesDavid A Amato, William N Malatestinic, Matthew C Palmgren, et al.Current Medical Research and Opinion|February 11, 2005
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomniaGary K Zammit, Louis J McNabb, Judy Caron, et al.Orphanet Journal of Rare Diseases|April 24, 2015
Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)Arian Pano, Ann J Barbier, Bonnie Bielefeld, et al.Primary Care Companion to the Journal of Clinical Psychiatry|January 26, 2010
The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot studyThomas Roth, Janet M Price, David A Amato, et al.The Journal of Investigative Dermatology|March 27, 2018
Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical PracticeJoseph F Merola, David A Amato, Kyoungah See, et al.Sleep|December 6, 2003
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomniaAndrew D Krystal, James K Walsh, Eugene Laska, et al.JAMA|December 17, 2009
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trialRobert C Green, Lon S Schneider, David A Amato, et al.Sleep|August 19, 2007
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitationsJames K Walsh, Andrew D Krystal, David A Amato, et al.Pageof 1